Trends in overall survival in lung adenocarcinoma with EGFR mutation, KRAS mutation, or no mutation
Background: Treatment of lung adenocarcinoma has changed and now includes checkpoint inhibitors (CPIs) or, in the case of an EGFR mutation, third-generation EGFR TKI osimertinib. Few data compare the long-term overall survival (OS) of current and historic subgroups. Methods: This real-world analysis...
Saved in:
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article (Journal) |
| Language: | English |
| Published: |
5 April 2025
|
| In: |
Cancers
Year: 2025, Volume: 17, Issue: 7, Pages: 1-17 |
| ISSN: | 2072-6694 |
| DOI: | 10.3390/cancers17071237 |
| Online Access: | Verlag, kostenfrei, Volltext: https://doi.org/10.3390/cancers17071237 Verlag, kostenfrei, Volltext: https://www.mdpi.com/2072-6694/17/7/1237 
|
| Author Notes: | Martin Faehling, Sabine Fallscheer, Birgit Schwenk, Harald Seifarth, Jörn Sträter, Claudia Lengerke and Petros Christopoulos |
MARC
| LEADER | 00000naa a2200000 c 4500 | ||
|---|---|---|---|
| 001 | 1937985156 | ||
| 003 | DE-627 | ||
| 005 | 20251008115053.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 251008s2025 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.3390/cancers17071237 |2 doi | |
| 035 | |a (DE-627)1937985156 | ||
| 035 | |a (DE-599)KXP1937985156 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 33 |2 sdnb | ||
| 100 | 1 | |a Faehling, Martin |d 1966- |e VerfasserIn |0 (DE-588)1171164823 |0 (DE-627)1040402135 |0 (DE-576)513619356 |4 aut | |
| 245 | 1 | 0 | |a Trends in overall survival in lung adenocarcinoma with EGFR mutation, KRAS mutation, or no mutation |c Martin Faehling, Sabine Fallscheer, Birgit Schwenk, Harald Seifarth, Jörn Sträter, Claudia Lengerke and Petros Christopoulos |
| 264 | 1 | |c 5 April 2025 | |
| 300 | |b Illustrationen | ||
| 300 | |a 17 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Gesehen am 08.10.2025 | ||
| 520 | |a Background: Treatment of lung adenocarcinoma has changed and now includes checkpoint inhibitors (CPIs) or, in the case of an EGFR mutation, third-generation EGFR TKI osimertinib. Few data compare the long-term overall survival (OS) of current and historic subgroups. Methods: This real-world analysis (KOMPASS study) included stage IV lung-adenocarcinoma patients with either EGFR, KRAS, or no mutation. Patients were assigned to the “current” EGFR, KRAS, or no-mutation cohort if they had mutation testing using NGS (n = 199; median date of diagnosis 2021). If they had an EGFR PCR test only, they were assigned to the “historic” EGFR or no-mutation cohort (n = 127; median date of diagnosis 2014). Results: Both the current and the historic EGFR cohorts had significantly longer OS than the respective no-mutation cohorts (HR 0.58 and 0.60, respectively). The current no-mutation and EGFR cohorts had a strong trend to longer OS than the respective historic cohorts. In the no-mutation cohorts, the improvement was due to an increase in long-term survivors (HR 0.71), whereas in the EGFR mutation cohorts, the median OS was improved without long-term survivors (HR 0.70). The KRAS cohort showed OS like the no-mutation cohort, with a plateau of long-term survivors around 20%. Conclusions: A comparison of our data with that of the phase III trials KEYNOTE-189 and FLAURA suggests that the improved outcomes are due to the use of CPIs or osimertinib. The clinical trial results are well translated into real-world clinical practice with comparable OS. KRAS patients benefit from CPI treatment like no-mutation patients. | ||
| 650 | 4 | |a <i>EGFR</i> | |
| 650 | 4 | |a <i>KRAS</i> | |
| 650 | 4 | |a check point inhibitor | |
| 650 | 4 | |a Exon 21 | |
| 650 | 4 | |a G12D | |
| 650 | 4 | |a lung cancer | |
| 650 | 4 | |a overall survival | |
| 650 | 4 | |a real-world data | |
| 700 | 1 | |a Fallscheer, Sabine |e VerfasserIn |4 aut | |
| 700 | 1 | |a Schwenk, Birgit |e VerfasserIn |4 aut | |
| 700 | 1 | |a Seifarth, Harald |e VerfasserIn |4 aut | |
| 700 | 1 | |a Sträter, Jörn |e VerfasserIn |4 aut | |
| 700 | 1 | |a Lengerke, Claudia |e VerfasserIn |4 aut | |
| 700 | 1 | |a Christopoulos, Petros |d 1977- |e VerfasserIn |0 (DE-588)138659702 |0 (DE-627)604886756 |0 (DE-576)308488067 |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Cancers |d Basel : MDPI, 2009 |g 17(2025), 7, Artikel-ID 1237, Seite 1-17 |h Online-Ressource |w (DE-627)614095670 |w (DE-600)2527080-1 |w (DE-576)313958548 |x 2072-6694 |7 nnas |a Trends in overall survival in lung adenocarcinoma with EGFR mutation, KRAS mutation, or no mutation |
| 773 | 1 | 8 | |g volume:17 |g year:2025 |g number:7 |g elocationid:1237 |g pages:1-17 |g extent:17 |a Trends in overall survival in lung adenocarcinoma with EGFR mutation, KRAS mutation, or no mutation |
| 856 | 4 | 0 | |u https://doi.org/10.3390/cancers17071237 |x Verlag |x Resolving-System |z kostenfrei |3 Volltext |
| 856 | 4 | 0 | |u https://www.mdpi.com/2072-6694/17/7/1237 |x Verlag |z kostenfrei |3 Volltext |
| 951 | |a AR | ||
| 992 | |a 20251008 | ||
| 993 | |a Article | ||
| 994 | |a 2025 | ||
| 998 | |g 138659702 |a Christopoulos, Petros |m 138659702:Christopoulos, Petros |d 910000 |d 950000 |d 950900 |d 50000 |e 910000PC138659702 |e 950000PC138659702 |e 950900PC138659702 |e 50000PC138659702 |k 0/910000/ |k 1/910000/950000/ |k 2/910000/950000/950900/ |k 0/50000/ |p 7 |y j | ||
| 999 | |a KXP-PPN1937985156 |e 478263689X | ||
| BIB | |a Y | ||
| SER | |a journal | ||
| JSO | |a {"person":[{"display":"Faehling, Martin","family":"Faehling","given":"Martin","role":"aut"},{"given":"Sabine","family":"Fallscheer","display":"Fallscheer, Sabine","role":"aut"},{"role":"aut","family":"Schwenk","display":"Schwenk, Birgit","given":"Birgit"},{"family":"Seifarth","display":"Seifarth, Harald","given":"Harald","role":"aut"},{"role":"aut","display":"Sträter, Jörn","family":"Sträter","given":"Jörn"},{"family":"Lengerke","display":"Lengerke, Claudia","given":"Claudia","role":"aut"},{"family":"Christopoulos","display":"Christopoulos, Petros","given":"Petros","role":"aut"}],"title":[{"title":"Trends in overall survival in lung adenocarcinoma with EGFR mutation, KRAS mutation, or no mutation","title_sort":"Trends in overall survival in lung adenocarcinoma with EGFR mutation, KRAS mutation, or no mutation"}],"physDesc":[{"noteIll":"Illustrationen","extent":"17 S."}],"relHost":[{"disp":"Trends in overall survival in lung adenocarcinoma with EGFR mutation, KRAS mutation, or no mutationCancers","name":{"displayForm":["Molecular Diversity Preservation International (MDPI)"]},"recId":"614095670","pubHistory":["1.2009 -"],"note":["Gesehen am 27.05.2020"],"origin":[{"publisherPlace":"Basel","dateIssuedDisp":"2009-","publisher":"MDPI","dateIssuedKey":"2009"}],"id":{"eki":["614095670"],"zdb":["2527080-1"],"issn":["2072-6694"]},"type":{"media":"Online-Ressource","bibl":"periodical"},"language":["eng"],"physDesc":[{"extent":"Online-Ressource"}],"title":[{"title_sort":"Cancers","title":"Cancers"}],"part":{"text":"17(2025), 7, Artikel-ID 1237, Seite 1-17","pages":"1-17","volume":"17","issue":"7","extent":"17","year":"2025"}}],"origin":[{"dateIssuedDisp":"5 April 2025","dateIssuedKey":"2025"}],"type":{"bibl":"article-journal","media":"Online-Ressource"},"id":{"eki":["1937985156"],"doi":["10.3390/cancers17071237"]},"language":["eng"],"name":{"displayForm":["Martin Faehling, Sabine Fallscheer, Birgit Schwenk, Harald Seifarth, Jörn Sträter, Claudia Lengerke and Petros Christopoulos"]},"recId":"1937985156","note":["Gesehen am 08.10.2025"]} | ||
| SRT | |a FAEHLINGMATRENDSINOV5202 | ||